These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 16060398)

  • 1. Production of matrix metalloproteinases and their inhibitors in osteoarthritic patients undergoing mud bath therapy.
    Bellometti S; Richelmi P; Tassoni T; Bertè F
    Int J Clin Pharmacol Res; 2005; 25(2):77-94. PubMed ID: 16060398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis.
    Kanyama M; Kuboki T; Kojima S; Fujisawa T; Hattori T; Takigawa M; Yamashita A
    J Orofac Pain; 2000; 14(1):20-30. PubMed ID: 11203734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of cytokines in osteoarthritis pathophysiology.
    Fernandes JC; Martel-Pelletier J; Pelletier JP
    Biorheology; 2002; 39(1-2):237-46. PubMed ID: 12082286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone.
    Hulejová H; Baresová V; Klézl Z; Polanská M; Adam M; Senolt L
    Cytokine; 2007 Jun; 38(3):151-6. PubMed ID: 17689092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip.
    Masuhara K; Nakai T; Yamaguchi K; Yamasaki S; Sasaguri Y
    Arthritis Rheum; 2002 Oct; 46(10):2625-31. PubMed ID: 12384920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis.
    Ishiguro N; Ito T; Ito H; Iwata H; Jugessur H; Ionescu M; Poole AR
    Arthritis Rheum; 1999 Jan; 42(1):129-36. PubMed ID: 9920023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
    Vandooren B; Kruithof E; Yu DT; Rihl M; Gu J; De Rycke L; Van Den Bosch F; Veys EM; De Keyser F; Baeten D
    Arthritis Rheum; 2004 Sep; 50(9):2942-53. PubMed ID: 15457463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
    Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both serum receptors of tumor necrosis factor are influenced by mud pack treatment in osteoarthrotic patients.
    Bellometti S; Galzigna L; Richelmi P; Gregotti C; Bertè F
    Int J Tissue React; 2002; 24(2):57-64. PubMed ID: 12182234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients.
    Lanchou J; Corbel M; Tanguy M; Germain N; Boichot E; Theret N; Clement B; Lagente V; Malledant Y
    Crit Care Med; 2003 Feb; 31(2):536-42. PubMed ID: 12576963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis.
    Jain A; Nanchahal J; Troeberg L; Green P; Brennan F
    Arthritis Rheum; 2001 Aug; 44(8):1754-60. PubMed ID: 11508425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
    Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
    Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B; Głowińska B; Urban M; Peczyńska J
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
    Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
    Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.